Sight Sciences, Inc. (SGHT) Earnings Call Analysis

NASDAQ · Healthcare · Medical Devices

21/25

Growth 5 Margin 5 Expansion 5 Platform 3 Financial 3

latest quarter score

Earnings Reports

21
Sight Sciences (SGHT) Q2 2026: Interventional Dry Eye Revenue Triples, Expanding Recurring Platform
August 06, 2026
20
Sight Sciences (SGHT) Q1 2026: Dry Eye Revenue Triples, Early Adoption Signals Scaling Path
May 07, 2026
16
Site Sciences (SGHT) Q4 2025: Interventional Dry Eye Revenue Triples, Unlocking Reimbursed TAM
March 05, 2026
14
Sight Sciences (SGHT) Q3 2025: TierCare Medicare Coverage Unlocks 10.4M Lives, Setting Stage for Interventional Dry Eye Growth
November 07, 2025
11
Sight Sciences (SGHT) Q2 2025: OmniEdge Drives 6% Account Growth Amid LCD Headwinds
August 08, 2025
10
Sight Sciences (SGHT) Q1 2025: $4M Tariff Headwind Drives Cost Discipline and Manufacturing Shift
July 05, 2025
Sight Sciences (SGHT) Q4 2024: Surgical Glaucoma Revenue Up 9% Amid Market Headwinds, Dry Eye Reimbursement Progress
March 05, 2025

Browse all companies